Peter Eickelmann

1.3k total citations · 1 hit paper
19 papers, 1.0k citations indexed

About

Peter Eickelmann is a scholar working on Molecular Biology, Surgery and Cellular and Molecular Neuroscience. According to data from OpenAlex, Peter Eickelmann has authored 19 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 7 papers in Surgery and 4 papers in Cellular and Molecular Neuroscience. Recurrent topics in Peter Eickelmann's work include Genomics, phytochemicals, and oxidative stress (6 papers), Pancreatic function and diabetes (6 papers) and Glutathione Transferases and Polymorphisms (4 papers). Peter Eickelmann is often cited by papers focused on Genomics, phytochemicals, and oxidative stress (6 papers), Pancreatic function and diabetes (6 papers) and Glutathione Transferases and Polymorphisms (4 papers). Peter Eickelmann collaborates with scholars based in Germany, United States and Italy. Peter Eickelmann's co-authors include Michael Mark, Rolf Grempler, Leo Thomas, Achim Sauer, Frank Himmelsbach, Matthias Eckhardt, Thomas Klein, Dale E. Sharp, Remko A. Bakker and Helmut Sies and has published in prestigious journals such as Journal of Biological Chemistry, FEBS Letters and Journal of Medicinal Chemistry.

In The Last Decade

Peter Eickelmann

19 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors

2011 494 citations Rolf Grempler, Leo Thomas et al. Diabetes Obesity and Metabolism profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Eickelmann Germany	13	662	534	408	70	68	19	1.0k
Kenji Katsuno Japan	12	372 0.6×	545 1.0×	292 0.7×	95 1.4×	114 1.7×	15	1.0k
Korekiyo Wakitani Japan	17	331 0.5×	339 0.6×	458 1.1×	86 1.2×	194 2.9×	31	1.1k
William R. Bensch United States	16	638 1.0×	347 0.6×	580 1.4×	298 4.3×	38 0.6×	18	1.6k
Sung-Hee Ihm South Korea	19	362 0.5×	314 0.6×	247 0.6×	104 1.5×	55 0.8×	61	1.0k
Junko Nakao Japan	19	323 0.5×	341 0.6×	139 0.3×	42 0.6×	182 2.7×	30	1.3k
Steven S. Mundt United States	15	375 0.6×	432 0.8×	398 1.0×	61 0.9×	95 1.4×	23	1.4k
Diane L. Crombie United States	9	701 1.1×	86 0.2×	141 0.3×	106 1.5×	47 0.7×	12	953
Samadhan Kshirsagar India	15	190 0.3×	247 0.5×	174 0.4×	34 0.5×	27 0.4×	44	556
Dale E. Sharp United States	12	361 0.5×	481 0.9×	324 0.8×	68 1.0×	57 0.8×	13	878
Natsumi Sawada Japan	19	335 0.5×	486 0.9×	63 0.2×	70 1.0×	24 0.4×	34	1.4k

Countries citing papers authored by Peter Eickelmann

Since Specialization

Citations

This map shows the geographic impact of Peter Eickelmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Eickelmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Eickelmann more than expected).

Fields of papers citing papers by Peter Eickelmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Eickelmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Eickelmann. The network helps show where Peter Eickelmann may publish in the future.

Co-authorship network of co-authors of Peter Eickelmann

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Eickelmann. A scholar is included among the top collaborators of Peter Eickelmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Eickelmann. Peter Eickelmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Jain, Ruchi, Deepak Jain, Q Liu, et al.. (2013). Pharmacological inhibition of Eph receptors enhances glucose-stimulated insulin secretion from mouse and human pancreatic islets. Diabetologia. 56(6). 1350–1355. 24 indexed citations

Brambillasca, Silvia, Sara Colombo, Peter Eickelmann, et al.. (2012). CDK5 Regulatory Subunit-associated Protein 1-Like 1 (CDKAL1) Is a Tail-anchored Protein in the Endoplasmic Reticulum (ER) of Insulinoma Cells. Journal of Biological Chemistry. 287(50). 41808–41819. 30 indexed citations

Thomas, Leo, Rolf Grempler, Matthias Eckhardt, et al.. (2011). Long‐term treatment with empagliflozin, a novel, potent and selective SGLT‐2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats. Diabetes Obesity and Metabolism. 14(1). 94–96. 42 indexed citations

Grempler, Rolf, Robert Augustin, Tobias Hildebrandt, et al.. (2011). Functional characterisation of human SGLT‐5 as a novel kidney‐specific sodium‐dependent sugar transporter. FEBS Letters. 586(3). 248–253. 60 indexed citations

Grempler, Rolf, Leo Thomas, Matthias Eckhardt, et al.. (2011). Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors. Diabetes Obesity and Metabolism. 14(1). 83–90. 494 indexed citations breakdown →

Grempler, Rolf, et al.. (2007). Inhibition of SH2‐domain containing inositol phosphatase 2 (SHIP2) in insulin producing INS1E cells improves insulin signal transduction and induces proliferation. FEBS Letters. 581(30). 5885–5890. 12 indexed citations

Busmann, Annette, Martin Wendland, C Berger, et al.. (2003). Identification and functional characterization of hemorphins VV‐H‐7 and LVV‐H‐7 as low‐affinity agonists for the orphan bombesin receptor subtype 3. British Journal of Pharmacology. 138(8). 1431–1440. 31 indexed citations

Weber, Dirk, C Berger, Peter Eickelmann, Jack P. Antel, & Horst Kessler. (2003). Design of Selective Peptidomimetic Agonists for the Human Orphan Receptor BRS-3. Journal of Medicinal Chemistry. 46(10). 1918–1930. 37 indexed citations

Weber, Dirk, C Berger, Timo Heinrich, et al.. (2002). Systematic optimization of a lead‐structure identities for a selective short peptide agonist for the human orphan receptor BRS‐3. Journal of Peptide Science. 8(8). 461–475. 20 indexed citations

10.

Schulz, Wolfgang A., et al.. (1997). Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics. 7(3). 235–239. 135 indexed citations

11.

Schulz, Wolfgang A., Peter Eickelmann, & Helmut Sies. (1996). Free Radicals in Toxicology:Redox Cycling and NAD(P)H:Quinone Oxidoreductase. Archives of toxicology. Supplement. 18. 217–222. 8 indexed citations

12.

Bier, H., Thomas K. Hoffmann, Peter Eickelmann, & D. Häfner. (1996). Chemosensitivity of head and neck squamous carcinoma cell lines is not primarily correlated with glutathione level but is modified by glutathione depletion. Journal of Cancer Research and Clinical Oncology. 122(11). 653–658. 12 indexed citations

13.

Eickelmann, Peter, Fabrice Morel, Wolfgang A. Schulz, & Helmut Sies. (1995). Turnover of Glutathione S‐Transferase α mRNAs is Accelerated by 12‐O‐Tetradecanoyl Phorbol‐13‐Acetate in Human Hepatoma and Colon Carcinoma Cell Lines. European Journal of Biochemistry. 229(1). 21–26. 8 indexed citations

14.

Sies, Helmut, Peter Eickelmann, & Wolfgang A. Schulz. (1995). Free radicals in toxicology: Redox cycling and nad(P)H: quinone oxidoreductase. Toxicology Letters. 78. 10–10. 1 indexed citations

15.

Eickelmann, Peter, Fabrice Morel, Wolfgang A. Schulz, & Helmut Sies. (1995). Turnover of Glutathione S-Transferase alpha mRNAs is Accelerated by 12-O-Tetradecanoyl Phorbol-13-Acetate in Human Hepatoma and Colon Carcinoma Cell Lines. European Journal of Biochemistry. 229(1). 21–26. 2 indexed citations

16.

Eickelmann, Peter, et al.. (1994). Loss of Heterozygosity at the NAD(P)H:Quinone Oxidoreductase Locus Associated with Increased Resistance against Mitomycin C in a Human Bladder Carcinoma Cell Line. Biological Chemistry Hoppe-Seyler. 375(7). 439–446. 46 indexed citations

17.

Eickelmann, Peter, Thomas Ebert, Ulrich Warskulat, Wolfgang A. Schulz, & Helmut Sies. (1994). Expression of NAD(P)H: quinone oxidoreductase and glutathione S-transferases α and π in human renal cell carcinoma and in kidney cancer-derived cell lines. Carcinogenesis. 15(2). 219–225. 28 indexed citations

18.

Ebert, Thomas, Heike Weber, Christiane Zoidl, et al.. (1994). Lowered amounts of the tissue-specific transcription factor LFB1 (HNF1) correlate with decreased levels of glutathione S-transferase alpha messenger RNA in human renal cell carcinoma.. PubMed. 54(5). 1319–23. 30 indexed citations

19.

Schulz, Wolfgang A., Peter Eickelmann, C Hallbrucker, Helmut Sies, & Dieter Häussinger. (1991). Increase of β‐actin mRNA upon hypotonic perfusion of perfused rat liver. FEBS Letters. 292(1-2). 264–266. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact